Market Overview - The IPO market in Hong Kong has shown a strong recovery, leading the global IPO fundraising rankings with a total of HKD 286.71 billion in 2025, a year-on-year increase of 225.9% [4] - The number of new listings reached 119, including 114 IPOs, marking a 62.9% increase compared to the previous year [4] IPO Market Characteristics Issuance Structure - The distribution of IPOs includes 8 super-large (over HKD 10 billion), 4 large (HKD 5-10 billion), 21 medium (HKD 2-5 billion), and 81 small (under HKD 2 billion) offerings, indicating growth across both large and small enterprises [4] Key Data - The Hang Seng Index rose by 27.77% over the year, outperforming major global stock markets, with total trading volume and average daily trading volume reaching historical highs [4] Investment and Intermediary Landscape Investment Institutions - 78.07% of IPOs included cornerstone investors, with total investments reaching HKD 106.60 billion, a record high [4] Intermediary Institutions - Chinese securities firms dominated the underwriting market, with CICC leading with 41 IPOs, followed by CITIC Securities and Huatai International [4] Policy and Filing Dynamics - In 2025, 187 companies completed the filing process for overseas listings, a 19.1% increase year-on-year, with 139 companies listing in Hong Kong, doubling from the previous year [4][5] Market Trend Outlook - The trend of technology companies going public in Hong Kong is expected to continue into the first half of 2026, supported by the influx of capital from both domestic and international sources [4] - The AI boom is driving ongoing interest in IPOs within the technology and semiconductor sectors, while healthcare and consumer sectors remain focal points for the market [4]

Group 1 - The Hong Kong IPO market in 2025 led the global capital markets with 114 companies raising approximately HKD 121.16 billion in listing fees, a year-on-year increase of HKD 64.62 billion, with listing fees accounting for about 4.24% of the total fundraising amount [1] - The top four IPO sponsors in 2025 were all Chinese firms, with CICC leading by sponsoring 41 companies, followed by CITIC Securities with 32, Huatai International with 22, and China Merchants International tied with Morgan Stanley at fourth place [2][3] - The participation of Chinese brokers in IPO sponsorship was significantly higher than that of foreign institutions, with only Morgan Stanley being the sole foreign firm in the top five [2][3] Group 2 - In 2025, 27 brokers acted as stabilizing agents for IPOs, with CICC leading by stabilizing 30 IPOs, followed by CITIC Securities with 16, and Morgan Stanley with 9 [4] - A total of 140 brokers participated as underwriters in the Hong Kong IPO market, with Futu Securities involved in 54 IPOs, followed closely by Agricultural Bank of China International with 53 [4] - The "Big Four" accounting firms dominated the auditing market for IPOs, collectively participating in 87% of the projects, with Ernst & Young leading by auditing 41 IPOs [5][6] Group 3 - In 2025, 34 mainland law firms provided legal services for Hong Kong IPOs, with Jingtian Gongcheng leading with 47 projects, doubling its participation from the previous year [7] - A total of 122 overseas law firms were involved in providing legal services for IPOs, with the top three being King & Wood Mallesons, DLA Piper, and Clyde & Co [9] - Eight industry consultants participated in 113 IPOs, with Frost & Sullivan being the most active, involved in 82 projects, capturing a market share of 73% [9]

Group 1 - The Hong Kong Securities and Futures Commission (SFC) and the Hong Kong Stock Exchange (HKEX) expressed concerns over the declining quality of IPO application materials and certain non-compliance behaviors in a joint letter to IPO sponsors [1] - Issues highlighted include poor quality of submitted listing documents, insufficient reviews, unclear descriptions of business models, selective presentation of industry data, and failure of sponsors to respond timely to regulatory feedback [1] - The SFC and HKEX continue to welcome quality enterprises to list in Hong Kong and are committed to maintaining the quality and standards of new listing applications [1] Group 2 - The Hong Kong IPO market has been very active this year, with 100 companies listed from January 1 to December 11, representing a year-on-year increase of 58.735% [2] - The total IPO fundraising amount exceeded HKD 270 billion, reaching HKD 270.86 billion, which is a year-on-year increase of 223.75%, making it the largest IPO fundraising globally [2] - A representative from a sponsoring institution indicated that the regulatory letter is a concern for sponsors' responsibilities and does not signal a tightening of IPO policies, aiming to prevent a focus on quantity over quality in the rapidly expanding IPO market [2]

Group 1 - The Hong Kong IPO market has raised funds amounting to 2.1 times the total for the entire year of 2024, with expectations for the Hong Kong Stock Exchange to regain the top position in IPO financing by 2025, projecting over HKD 300 billion in IPO fundraising for next year [1] - The trading volume of placement and convertible bond products has significantly increased year-on-year, with major blue-chip companies such as BYD, Xiaomi, Alibaba, China Pacific Insurance, Ping An Insurance, Chow Tai Fook Jewelry, and NIO completing large-scale transactions exceeding USD 1 billion [1] Group 2 - The primary market for Hong Kong stocks is showing a strong recovery, with influential companies actively responding to the national strategy to develop Hong Kong's capital market, leading to the execution of large-scale financing projects [2] - CATL's IPO raised USD 5.3 billion, becoming the largest IPO globally in 2023, and has facilitated other leading companies like Zijin Mining, Sany Heavy Industry, Seres, Hansoh Pharmaceutical, Sanhua Intelligent Controls, Haitian Flavoring and Food, and Chery Automobile to complete financing exceeding USD 1 billion, occupying four spots in the global top ten IPOs [2]

Core Insights - The Hong Kong IPO market remains robust, with expectations for strong activity to continue at least until 2026, driven by significant fundraising from large IPO projects [1] - In the first 11 months of this year, 91 companies successfully listed, raising a total of HKD 259.89 billion, marking a historic high and positioning Hong Kong as the leading exchange for global IPO fundraising in 2025 [1][3] - Chinese brokers have taken a dominant role in the Hong Kong IPO underwriting market, with over half of the 38 participating institutions being of Chinese background [1][5] Group 1: Market Characteristics - Large IPOs have become the core driver of the market, with significant contributions from A-share companies; 6 out of the top 10 IPOs this year were from A-share listed companies [3] - The IPO issuance shows clear seasonal patterns, with peak periods from March to June and September to November, accounting for over 70% of listings [3] - The new regulations have led to a surge in average first-day returns to 38%, with the first-day failure rate dropping to a five-year low of 23.08% [3] Group 2: Investor Participation - Investor enthusiasm is at an all-time high, with an average oversubscription rate of 1,675.24 times, a significant increase of 4.61 times year-on-year; a record oversubscription of 11,465 times was achieved by Jinye International Group [3][4] - The structure of cornerstone investors has diversified historically, with sovereign funds from the Middle East and Singapore participating for the first time, contributing valuable capital and international perspectives [4] Group 3: Underwriting Landscape - The market structure has become clearer, with leading institutions showing sustained advantages; Chinese brokers have solidified their dominance in the IPO underwriting business [4][5] - CICC leads the industry with 34 projects, followed by CITIC Securities with 26, and Huatai Financial Holdings with 18, all being Chinese firms [5] Group 4: Future Outlook - The Hong Kong IPO market is entering a new phase, with expectations for steady growth and structural deepening in 2026, influenced by both positive and negative factors [6] - Positive factors include the gradual return of international long-term capital, the transformation of the Chinese economy, supportive policies, and an increase in "A+H" listings [6] - However, uncertainties in the global macroeconomic environment and geopolitical tensions may pose challenges to market liquidity [6]

Core Insights - The Hong Kong IPO market has seen a strong recovery since 2025, with fundraising exceeding HKD 200 billion, regaining its position as the global leader in IPOs [1] - UBS has played a pivotal role in this resurgence, leading significant projects such as the listings of Mixue Ice City and CATL, and participating in BYD's placement [1][2] - The outlook for the Hong Kong IPO market remains positive, driven by the influx of quality companies and the return of foreign capital [1][6] Market Performance - The fundraising in the Hong Kong IPO market has surpassed expectations, with the market returning to the top globally in the first three quarters of the year [2] - The "924 policy" introduced last year signaled a positive shift, with high-quality foreign investors showing strong interest in projects like China Resources Beverage [2] - UBS's role in BYD's placement, raising approximately HKD 435 billion (around USD 56 billion), has significantly boosted market confidence [2] Representative Projects - Mixue Ice City is highlighted as a landmark project that opened the IPO market in Q1, setting a record for frozen capital and demonstrating strong institutional demand [3] - CATL's successful listing, with a "0 discount" pricing strategy, reflects the positive trend of domestic and foreign capital participation [3] Impact of HKEX Reforms - Recent reforms by the Hong Kong Stock Exchange (HKEX) have positively influenced the market, allowing larger companies to issue shares at more reasonable scales [4] - The new regulations have stabilized the allocation ratio between institutional and retail investors, enhancing pricing mechanisms and improving post-listing performance [4] Foreign Capital Trends - There is a clear trend of foreign capital returning to the Hong Kong IPO market, particularly from Europe and the Middle East [5] - The shift in foreign investment is driven by the need for diversified asset allocation, with China becoming a key focus for global investors [5] Future Outlook - The outlook for the Hong Kong IPO market in the next 1-2 years remains optimistic, supported by a positive cycle of supply and demand [6] - Key trends include diversification in company size and industry, a strong linkage between supply and demand, and the globalization of Chinese enterprises [7]

Core Insights - The Hong Kong IPO market has experienced a strong recovery since 2025, with fundraising exceeding HKD 200 billion, regaining the top position globally [1] - UBS has played a significant role in this resurgence, leading notable projects such as the listings of Mixue Ice Cream and CATL, and participating in BYD's placement [1] Market Performance - The performance of the Hong Kong IPO market this year has exceeded initial expectations, with a notable increase in high-quality foreign investments following the "924 policy" last year [2] - UBS coordinated a significant placement for BYD, raising approximately HKD 435 billion (around USD 56 billion), primarily from foreign investors, which boosted market confidence [2] Representative Projects - Key projects like Mixue Ice Cream have marked the opening of the IPO market this year, achieving record frozen capital and demonstrating strong demand from institutional investors [3] - CATL's successful listing with a "0 discount" pricing strategy further illustrates the positive trend of domestic and foreign capital participation in the market [3] Impact of HKEX Reforms - Recent reforms by the Hong Kong Stock Exchange (HKEX) have positively influenced the market, allowing larger companies to issue shares at more reasonable proportions, encouraging high-quality issuers to list [4] - The new regulations have stabilized the retail investor allocation at around 10%, aligning with international practices and enhancing institutional pricing power [5] Foreign Capital Trends - There is a clear trend of foreign capital returning to the Hong Kong IPO market, particularly from Europe and the Middle East, with increased participation from long-term foreign cornerstone investors [6] - The shift in foreign investment is driven by a need for diversified asset allocation, with China becoming a key focus for global investors [7] Future Outlook - The outlook for the Hong Kong IPO market remains positive, supported by a cycle where good supply creates good demand, with many high-growth companies planning to list [8] - Three key trends defining the future of the Hong Kong IPO market are "diversification," "supply-demand linkage," and "globalization," indicating a multi-faceted growth trajectory [9]

Core Viewpoint - Changfeng Pharmaceutical has successfully entered the inhalation drug market, traditionally dominated by multinational companies, by listing on the Hong Kong Stock Exchange after 18 years of effort [1][2]. Group 1: Company Overview - Changfeng Pharmaceutical officially listed on the Hong Kong Stock Exchange on October 8, 2023, with an IPO price of HKD 14.75 per share, and saw its stock price surge to HKD 48, marking a 225.42% increase on the first day [1]. - The company achieved a net profit of RMB 31.72 million in 2023, reversing a loss of RMB 49.39 million in 2022, and projects a revenue of RMB 608 million for 2024, with a compound annual growth rate (CAGR) of 31.9% from 2022 to 2024 [2][6]. - The company has approximately 40 research and development pipelines, with four products approved by the National Medical Products Administration of China and one product approved by the FDA [6]. Group 2: Market Performance - The public offering of Changfeng Pharmaceutical was oversubscribed by nearly 6,700 times, indicating strong market interest and investor confidence in the company's competitive edge [2][3]. - The Hong Kong IPO market has seen a significant increase in activity, with 68 IPOs completed in the first three quarters of 2023, a 51.11% increase from the previous year, and total fundraising reaching HKD 182.4 billion, up 228% year-on-year [10]. Group 3: Competitive Landscape - The inhalation drug market in China is highly concentrated, with the top five products accounting for 69.6% of the market share, and Changfeng's core product, CF017, holds approximately 16% of the market share for budesonide inhalation drugs [5][6]. - Despite strong initial market performance, Changfeng Pharmaceutical faces significant risks, particularly its heavy reliance on the CF017 product, which accounted for 96.2% of total revenue in 2022 and is projected to decline in growth [7][8]. Group 4: Future Outlook - The company plans to use approximately 40% of the IPO proceeds for research and development of inhalation drug candidates, 30% for expanding production facilities, and 20% for supporting other pipelines [2][6]. - Analysts suggest that the company must diversify its product offerings and continue to innovate to mitigate risks associated with dependence on a single product and to navigate the competitive landscape effectively [12].

Core Viewpoint - The Hong Kong IPO market has experienced unprecedented subscription enthusiasm in 2023, with record oversubscription rates and significant increases in both the number of new listings and total fundraising amounts [1][3]. Group 1: Market Performance - In the first three quarters of 2023, Hong Kong is expected to see 66 new listings, raising a total of HKD 182.3 billion, a 47% increase in the number of new listings and a 228% increase in fundraising compared to the same period last year [1]. - The average first-day return for new IPOs in Hong Kong was 33% in the first half of 2023, significantly higher than the 9% recorded in the same period last year [7]. - 98% of new stocks received oversubscription, with 87% of them being oversubscribed by more than 20 times [7]. Group 2: Sector Analysis - The medical and pharmaceutical sectors had the highest number of new listings, while the manufacturing sector led in fundraising, primarily driven by the large-scale IPO of CATL [8]. - The top five new IPOs in 2023 all raised over HKD 10 billion, with total fundraising for these projects increasing by 135% year-on-year to HKD 98.7 billion [8]. Group 3: Regulatory and Policy Support - The China Securities Regulatory Commission announced measures to support leading domestic companies in listing in Hong Kong, which is expected to enhance the IPO market [3]. - The Hong Kong Stock Exchange has received 283 listing applications in the first eight months of 2025, a 123% year-on-year increase [3]. Group 4: Future Outlook - Deloitte forecasts that Hong Kong will continue to see strong momentum in the IPO market, with over 80 new listings expected in 2025, raising between HKD 250 billion and HKD 280 billion [1]. - The influx of overseas funds into Hong Kong is anticipated to support large-scale IPOs in the fourth quarter of 2023, creating a favorable valuation environment [1][3].

Core Insights - The Hong Kong IPO market has seen unprecedented subscription enthusiasm this year, with record oversubscription rates, including a leading 7558 times for a major IPO [1] - Deloitte's report predicts that Hong Kong will continue to lead the global IPO fundraising rankings, with 66 new listings expected in the first three quarters of 2023, raising a total of HKD 182.3 billion, a 228% increase from the previous year [1][3] - The report anticipates that the strong momentum will continue into the last quarter of 2023, with over 80 new listings expected in 2025, raising between HKD 250 billion to HKD 280 billion [1][3] Market Dynamics - Six super-large IPOs are expected in 2023, including five A+H shares and one spin-off from an A+H listed company, alongside four large IPOs [3][4] - The China Securities Regulatory Commission has introduced measures to support leading domestic companies in listing in Hong Kong, enhancing the regulatory framework for overseas listings [3][4] - The average daily trading volume in the Hong Kong stock market has remained above HKD 200 billion, contributing to an overall increase in company valuations [4] Performance Metrics - The average first-day return for new IPOs in Hong Kong was 33% in the first half of 2023, significantly higher than the 9% recorded in the same period last year [7] - 98% of new IPOs this year received oversubscription, with 87% achieving oversubscription rates exceeding 20 times [7] - The top five new IPOs this year all raised over HKD 10 billion, with total fundraising for these five reaching HKD 98.7 billion, a 135% increase year-on-year [8][10] Sector Analysis - The manufacturing sector accounted for the highest proportion of fundraising in the first three quarters of 2023, at 37%, followed by the consumer sector at 20% and the energy and resources sector at 16% [10][11] - The healthcare and pharmaceutical sectors had the highest number of IPOs, while the manufacturing sector led in fundraising amounts, driven by the large IPO of CATL [7][10] Investment Appeal - The diverse distribution of industries in the Hong Kong IPO market enhances its attractiveness to foreign capital, providing various sector allocation opportunities [11] - The A+H listed companies benefit from easy capital flow in the Hong Kong market, often trading at a discount, creating a valuation opportunity for value investors [11]